EQS-News: Formycon joins the SDAX of the German Stock Exchange

Press Release // December 5, 2024

Formycon joins the SDAX of the German Stock Exchange

• Formycon shares will be part of the Dax index family, ranking among the 70 largest German companies below the MDAX
• Enhanced share attractiveness following recent uplisting to the Prime Standard
• Formycon shares to be included in the index effective as of December 23, 2024

Planegg-Martinsried, Germany – Formycon AG (WKN: A1EWVY ISIN: DE000A1EWVY8) will join the SDAX of Deutsche Börse, just a few weeks after its successful uplisting to the Prime Standard. As of December 23, 2024, Formycon will officially be part of the Small-Cap Index. The decision was announced yesterday during Deutsche Börse’s regular index review. With its inclusion in the SDAX, Formycon will now rank among the 70 largest publicly listed companies in Germany below the DAX and MDAX, based on the market capitalization of freely tradable shares (free float).

“Joining the SDAX is a significant milestone for Formycon and a remarkable event in our capital market history, which further strengthens our position and visibility in the capital market. Following our inclusion in the MSCI Germany Small Cap Index last year, being listed in the SDAX is yet another testament to the success of our capital market strategy and the outstanding work of the entire Formycon team,” said Enno Spillner, CFO of Formycon AG.

The inclusion in the SDAX supports Formycon’s growth strategy and ongoing evolution as a leading biosimilar developer. From its initial listing on the Open Market in 2010 to its uplisting to the Prime Standard in November 2024, the Company has consistently aligned itself with capital market requirements, laying the foundation for its exceptionally positive business development in recent years.

About Formycon:

Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, received FDA approval; FYB202 is also approved in Europe. Another three biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich and is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com

About Biosimilars:

Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:

Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 - 86 46 67 149
Fax: + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com

Disclaimer:

This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.